Prot #GS-US-342-1138: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks in Subjects with Chronic HCV

Project: Research project

Project Details

StatusFinished
Effective start/end date8/15/148/15/17

Funding

  • PRA Health Sciences (GS-US-342-1138)
  • Gilead Sciences, Inc. (GS-US-342-1138)